AU2003200660B2 - Collagen Mimics - Google Patents
Collagen Mimics Download PDFInfo
- Publication number
- AU2003200660B2 AU2003200660B2 AU2003200660A AU2003200660A AU2003200660B2 AU 2003200660 B2 AU2003200660 B2 AU 2003200660B2 AU 2003200660 A AU2003200660 A AU 2003200660A AU 2003200660 A AU2003200660 A AU 2003200660A AU 2003200660 B2 AU2003200660 B2 AU 2003200660B2
- Authority
- AU
- Australia
- Prior art keywords
- collagen
- xaa
- peptide
- amino acid
- flp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 102000008186 Collagen Human genes 0.000 title claims description 131
- 108010035532 Collagen Proteins 0.000 title claims description 131
- 229920001436 collagen Polymers 0.000 title claims description 131
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 25
- 230000003278 mimic effect Effects 0.000 claims description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 125000000539 amino acid group Chemical group 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- -1 trifluoromethyl modified hydroxyproline Chemical class 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- ZPBIYZHGBPBZCK-VKHMYHEASA-N (2s)-4,4-difluoropyrrolidin-1-ium-2-carboxylate Chemical compound OC(=O)[C@@H]1CC(F)(F)CN1 ZPBIYZHGBPBZCK-VKHMYHEASA-N 0.000 claims description 3
- 238000011160 research Methods 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 12
- 230000001939 inductive effect Effects 0.000 description 12
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 12
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 230000015572 biosynthetic process Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 229960002429 proline Drugs 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 238000007385 chemical modification Methods 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 235000013930 proline Nutrition 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 229920001184 polypeptide Polymers 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 5
- 125000001153 fluoro group Chemical group F* 0.000 description 5
- 229960002591 hydroxyproline Drugs 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 229910000679 solder Inorganic materials 0.000 description 5
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 5
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 4
- 230000003466 anti-cipated effect Effects 0.000 description 4
- 238000002983 circular dichroism Methods 0.000 description 4
- 230000008878 coupling Effects 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000005859 coupling reaction Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 3
- 229920001222 biopolymer Polymers 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 210000000845 cartilage Anatomy 0.000 description 3
- 238000001142 circular dichroism spectrum Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- KZMRGTASBWZPFC-BYPYZUCNSA-N (2s)-1-fluoropyrrolidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1F KZMRGTASBWZPFC-BYPYZUCNSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007327 hydrogenolysis reaction Methods 0.000 description 2
- 230000033444 hydroxylation Effects 0.000 description 2
- 238000005805 hydroxylation reaction Methods 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000000515 tooth Anatomy 0.000 description 2
- 125000003508 trans-4-hydroxy-L-proline group Chemical group 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 1
- HDIWYDAOZBOJPA-RITPCOANSA-N (2s,4r)-1-acetyl-4-fluoropyrrolidine-2-carboxylic acid Chemical compound CC(=O)N1C[C@H](F)C[C@H]1C(O)=O HDIWYDAOZBOJPA-RITPCOANSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical compound ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 240000007049 Juglans regia Species 0.000 description 1
- 235000009496 Juglans regia Nutrition 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 239000012346 acetyl chloride Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- WCIXKWOJEMZXMK-ZETCQYMHSA-N methyl (2s)-1-acetylpyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1CCCN1C(C)=O WCIXKWOJEMZXMK-ZETCQYMHSA-N 0.000 description 1
- RRXCEVZGPPDCGR-RQJHMYQMSA-N methyl (2s,4r)-1-acetyl-4-hydroxypyrrolidine-2-carboxylate Chemical compound COC(=O)[C@@H]1C[C@@H](O)CN1C(C)=O RRXCEVZGPPDCGR-RQJHMYQMSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 150000003148 prolines Chemical class 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- VPAYJEUHKVESSD-UHFFFAOYSA-N trifluoroiodomethane Chemical compound FC(F)(F)I VPAYJEUHKVESSD-UHFFFAOYSA-N 0.000 description 1
- 235000020234 walnut Nutrition 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
S&F Ref: 496010D1
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION FOR A STANDARD PATENT
ORIGINAL
Name and Address of Applicant: Actual Inventor(s): Address for Service: Invention Title: Wisconsin Alumni Research Foundation 614 Walnut Street Madison Wisconsin 53705 United States of America Ronald T Raines Spruson Ferguson St Martins Tower,Level 31 Market Street Sydney NSW 2000 (CCN 3710000177) Collagen Mimics The following statement is a full description of this invention, including the best method of performing it known to me/us:- 5845c COLLAGEN MIMICS
BACKGROUND
Collagen is the most abundant protein in vertebrates, occurring in virtually every tissue, including skin, tendon, bone, blood vessel, cartilage, ligament, and teeth.
Collagen serves as the fundamental structural protein for vertebrate tissues. Collagen abnormalities are associated with a wide variety of human diseases, including arthritis, rheumatism, brittle bones, atherosclerosis, cirrhosis, and eye cataracts. Collagen is also critically important in wound healing. Increased understanding of the structure of collagen, and of how its structure affects its stability, facilitates the development of new treatments for collagen-related diseases and improved wound healing treatments.
Collagen is a fibrous protein that can exist in a variety of related forms.
Mammals produce at least 17 distinct polypeptide chains that combine to form at least variants of collagen. In each of these variants, the polypeptide chains of collagen are composed of approximately 300 repeats of the sequence X-Y-Gly, where X is often a proline (Pro) residue and Y is often a 4(R)-hydroxyproline (Hyp) residue. In connective tissue.(such as bone, tendon, cartilage, ligament, skin, blood vessels, and teeth), individual collagen molecules are wound together in tight triple helices. These helices are organized into fibrils of great tensile strength, Jones Miller, J. Mol. Biol., 218:209- 219 (1991). Varying the arrangements and cross linking of the collagen fibrils enables vertebrates to support stress in one-dimension (tendons), two-dimensions (skin), or threedimensions (cartilage).
In vertebrates, the collagen polypeptide is translated with the typical repeat motif being ProProGly. Subsequently, in vivo, the hydroxylation of Pro residues is performed enzymatically after collagen biosynthesis but before the chains begin to form a triple helix. Thus, hydroxylation could be important for both collagen folding and collagen stability. The hydroxyl group of Hyp residues has long been known to increase the thermal stability of triple-helical collagen, Berg and Prockop, Biochem. Biophys. Res.
Comm., 52:115-120 (1973). For example, the melting temperature of a triple helix of (ProHypGly)o chains is 58° C, while that of a triple helix of (ProProGly),, chains is only 24° C, Sakakibara et al., Biochem. Biophys. Aca, 303:198-202 (1973). In addition, the rate at which (ProHypGly),, chains fold into a triple helix is substantially greater than the corresponding rate for (ProProGly),o chains, Chopra and Ananthanarayanan, Proc. Natl.
Acad. Sci. USA, 79:7180-7184 (1982). The molecular basis for these observed effects is, however, not clear.
Molecular modeling based on the structure of triple-helical collagen and conformational energy calculations suggest that hydrogen bonds cannot form between the hydroxyl group of Hyp residues and any main chain groups of any of the collagen molecules in the same triple helix, Okuyama et al., I. Mol. Biol., 152:427-443 (1981).
Several models include the hypothesis that hydroxyproline increases the stability of collagen as a result a bridge of water molecules formed betweenthe-hydroxyl group and a main chain carbonyl group. For reviews of observations advancing this hypothesis, see: Suzuki et al., Int. I. Biol. Macromol., 2:54-56 (1980), and Nmethy, in Collagen, published by CRC press (1988), and the references cited therein.
However, there exists experimental evidence that is inconsistent with the bridging water molecule model. For example, the triple helices of (ProProGly),, and (ProHypGly)io were found to be stable in 1,2-propanediol, and Hyp residues conferred added stability in these anhydrous conditions, Engel et al., Biopolymers, 16:601-622 (1977), suggesting that water molecules do not play a part in the added stability of (ProHypGly)o. In addition, heat capacity measurements are inconsistent with collagen having more than one bound water per six Gly-X-Y units, Hoeve and Kakivaya, Phys.
Chem., 80:754-749 (1976). Accordingly, there exists no prior definitive demonstration of the m-6chanism by which the hydroxyproline residues stabilizes collagen triplexes.
A better understanding of how the structure of collagen contributes to its stability would facilitate the design of a collagen or collagen mimics having improved stability.
A high stability collagen substitute could advance the development of improved wound healing treatments.
In recent years, there have been exciting developments in wound healing, including the development of tissue engineering and tissue welding. For example, autologous epidermal transplantation for the treatment of burns was a significant advance in tissue engineering. Tissue engineering has also led to the development of several types of artificial skin, some of which employ human collagen as a substrate.
However, a major problem associated with this treatment is the fragility of these grafts during and after surgery.
Tissue welding is a wound healing technique in which a laser is used to thermally denature the collagen in the skin at the periphery of a wound. The wound is reannealed by permitting the renaturation of the collagen. In the case of large wounds, a "filler" or solder is required to effect reannealing of the wound. Various materials, including human albumin, have been used as solders for this purpose. A good solder is resilient and is non-immunogenic and should preferably be capable of interaction with native collagen in adjacent sites.
Collagen is also used for a variety of other medical purposes. For example, collagen is used in sutures which can be naturally degraded by the human body and thus do not have to be removed following recovery. A sometimes limiting factor in the design of collagen sutures is the strength of the collagen fibers. A collagen variant or mimic having a greater strength would aid in the usage of such collagen sutures by relieving this limitation.
What is needed in the art is a novel collagen having increased stability for use in artificial skin, as a solder in tissue welding, and as a general tool for use in the design of medical constituents.
Fluoroproline (Flp) was synthesized by Gottleib et al., Biochemistry, 4: 11: 2507- 2513 (1965) in both R and S stereoisomers. Gottleib et al. claimed to have incorporated both isomers into collagen by a biosynthetic route, but that claim was later refuted by Takeuchi et al., Biochem. Biophys. Acta, 175: 156-164 (1969), Takeuchi and Prockop, Biochem. Biophys. Acta, 175: 142-155 (1969), and Uitto and Prockop, Arch. Biochem.
Biophys., 181: 293-299 (1977). Because Gottleib et al. used biosynthesis, to the extent that Flp was incorporated at all into the resulting collagen molecules, it would have been incorporated randomly into the polypeptide in place of some random proline residues.
There is, of course, no codon specific for Flp. The Flp was also a racemic mixture of both stereoisomers further randomizing the nature of the proteins produced, if the Flp was incorporated at all, which is significantly in doubt. Others have studied the chemical properties of Flp without incorporating it into a larger polypeptide, Gerig and McLeod, J.
Am. Chem. Soc., 98: 3970-3975 (1976).
Summary of the Invention According to a first embodiment of the invention, there is provided a collagen mimic comprising a tripeptide having the formula: (Xaa-Flp-Gly)n, where Xaa is any amino acid residue, Flp is 4(R)-fluoroproline, and n is a positive integer.
According to a second embodiment of the invention, there is provided a composition of matter comprising a triple helix of collagen mimic molecules in which each of the molecules in the helix comprises tripeptides of the formula: (Xaa-Flp-Gly)n, where Xaa is any naturally occurring amino acid, Flp is 4(R)-fluoroproline, and n is a positive integer.
According to a third embodiment of the invention, there is provided a collagen mimic comprising a tripeptide having the formula: (Xaa-Xbb-Gly)n, where Xaa is any amino acid residue, [R:\LlBFF]26070spec.doc:gcc 4a Xbb is selected from the group consisting of 4(R)-fluoroproline, mesly modified hydroxyproline, and trifluoromethyl modified hydroxyproline, and n is a positive integer.
According to a fourth embodiment of the invention, there is provided a collagen mimic comprising a tripeptide having the formula: (Xaa-Xbb-Gly)n, where Xaa is any amino acid residue, Xbb is selected from the group consisting of 4(R)-fluoroproline, 4(S)-fluoroproline, 4,4-difluoroproline, and n is a positive integer.
The present invention is summarized in that a novel variant of collagen has been designed which forms a stronger triple helix than does native collagen. The novel variant includes a fluorinated proline residue substituted for the hydroxyproline residue characteristic of the triple repeats normally found in native collagen.
It is an object of the present invention to provide a novel, high stability collagen molecule that could be used as a component in artificial skin, as a solder in tissue welding, or as a substitute for collagen in other applications requiring high strength.
It is a feature of the present invention that evidence is provided to demonstrate the nature of the additional stability added to collagen by the Hyp residue, thereby making it possible to design other residues for that position which would add to that stability.
The present invention features a novel collagen mimic having increased strength and describes alternative methods by which that molecule can be made.
Other objects, advantages, and features of the present invention will become apparent upon review of the specification, drawings, and claims.
R:\PAL Specifications\496010]26070spec.doc:gcc DESCRIPTION OF THE DRAWINGS Fig. I shows the circular dichroism spectra of (Pro-Flp-Gly) 1 o, (ProProGly),o, and (ProHypGly)i0.
Fig. 2 illustrates the synthetic route for the production of FmocProFlpGlyOH, as described in the examples below.
Fig. 3 illustrates the synthetic route for the production of (ProFlpGly),o, as described in the examples below.
DETAILED DESCRIPTION OF THE INVENTION The investigation that lead to the work described here began with the notion that a better understanding of the factors that contribute to the three dimensional structure and stability of collagen would facilitate the design of a collagen variant having improved strength for use in wound healing, and the development of treatments for people suffering from collagen-related illnesses. It would also provide a general purpose stronger collagen for a variety of purposes.
The hypothesis underlying this study was the belief that bridging water molecules are unlikely to contribute significantly to collagen stability. First, immobilizing one or more water molecules for each Hyp residue would evoke an enormous entropic cost. A water molecule can form 4 hydrogen bonds. In bulk aqueous solution, these 4 hydrogen bonds are formed with other water molecules that are themselves mobile. In contrast, the bridging water molecules of collagen would suffer a far greater loss of entropy because two of their hydrogen bonds would be with collagen, which is immobile relative to a water molecule.
Second, if the bridging water molecules of collagen are indeed important for collagen stability, then it is likely that they would be homogeneous, with one hydrogenbonding pattern predominating. However, a high-resolution three-dimensional structure of triple-helical collagen suggested that individual Hyp residues bond to 1, 2, 3, or 4 water molecules, forming irregular, complex networks of intrachain or interchain hydrogen bonds, Bella et al., Science, 266:75-81 (1994). This heterogeneity and complexity in the hydrogen bonding is inconsistent with the hypothesis that bridging water molecules confer stability to collagen.
Proposed here is an alternative explanation for collagen stability that is based on the influence of inductive effects on collagen conformation and stability. The Hyp residues in crystalline collagen do not have unusual 4 or cp bond angles. But, I angles (which are the dihedral angles of the peptide bond) merit consideration. The trans isomer (that is, the isomer with G3 1800) of a proline peptide bond is only slightly favored over the cis isomer (that is, the isomer with Yet according to the structure of crystalline collagen, all of the peptide bonds in triple-helical collagen are in the trans conformation. This leads to the hypothesis that Hyp residues could favor the trans conformation.
To begin to test this hypothesis, it was determined how electron-withdrawing groups affect the trans:cis ratio. N-Acetyl proline methylester (AcProOMe), N-acetyl- 4(R)-hydroxyproline methylester (AcHypOMe), and N-acetyl-4(R)-fluoroproline (AcFlpOMe) were synthesized and their preferences for the trans state were determined, Eberhardt et al., I. Am. Chem. Soc., 118:12261-12266 (1996). The trans:cis ratio was found to increase in the order: AcProOMe <AcHypOMe <AcFlpOMe (Table 1).
Because the trans isomer is the only isomer found in triple helical collagen, this order suggests that the FIp residue will stabilize triple helical collagen more than the Hyp residue, and that the Hyp residue will stabilize triple helical collagen more than the Pro residue.
The origin of this effect on trans:cis ratio was explored by determining the crystalline structures of AcProOMe, AcHypOMe, and AcFlpOMe, Panasik et al., Int. i.
Pept. Protein Res., 44:262-269. The Cy-C6 bond length was found to decrease in the order: AcProOMe AcHypOMe AcFlpOMe (Table This order is consistent with an inductive effect in which the substituent in the 4-position withdraws electron density away from the Cy-C5 bond. A shorter Cy-C6 bond length diminishes steric clashes between atoms in the trans isomer, but has no effect on the cis isomer. The inductive effect from the hydroxyl group of Hyp residues is consistent with the effect of Hyp on collagen stability. Other manifestations of the inductive effects of Hyp and FIp residues were also found by Panasik et al. and by Eberhardt et al. Similar inductive effects should be manifested in 4(S)-fluoroproline and in 4,4-difluoroproline.
I
Table 1: Inductive effect on the properties of AcProOMe, AcHypOMe, and AcFIpOMe MG Cy-C6 bond length trans:cis ratio (kcal/mol) (A) AcProOMe 4.3 0 1.523 AcHypOMe 5.8 0.18 1.510 AcFlpOMe 6.2 0.22 1.508 This result suggests that if evolution has placed a Hyp residue in the middle position of the triple repeat motif of collagen due to its the inductive effect that draws electron density toward the hydroxyl group of the Hyp residue, then a residue having a substituent which exhibits an even greater inductive effect should be capable of forming a collagen triple helix that is even stronger than native collagen. This invention is based on this premise and the data presented here supports the hypothesis. The placement of the fluorine atom in the 4 position in the proline in 4(R)-fluoroproline (Flp), and the incorporation of FIp into collagen triple helixes, as described below, does in fact increase the strength of the collagen triple helix formation. Thus the intelligent design of improved collagen mimics is enabled for the first time.
To test the role of the inductive effect on collagen stability, the collagen mimic (Xaa-Flp-Gly),o was synthesized, where Flp is 4(R)-fluoro-L-proline, as described in detail in the examples below. In Fip residues, the fluorine atom imposes a strong inductive effect, but does not form hydrogen bonds. The thermal stabilities and helicity of (ProFlpGly),o, (ProProGly),o, and (ProHypGly),owere determined using circular dichroism. The collagen mimic (ProFlpGly),, was found to form a very stable triple helical collagen, stronger than either of the other forms tested. This demonstrates not only that the collagen mimic (ProFipGiy)o is useful as a collagen mimic for making collagen compatible materials, but that the critical parameter in the formation of the collagen triple helix structure is the inductive effect on electron density at the 4 position in the proline in the middle position of the triple repeat motif. Forms of collagen mimics having other amino acids at the first position in the triple motif is contemplated here.
The present invention is a collagen mimic comprising a triple repeat motif peptide having the formula (XaaFlpGly)n, where Flp is 4(R)-fluoro-L-proline, n is a positive integer, and Xaa is any amino acid, but is typically one of the 20 naturally occurring amino acids. In the examples below, the collagen mimics that were synthesized and tested had a proline residue at position Xaa. It is anticipated that amino acids other than proline would be tolerated in the Xaa position, given that natural collagen hfasa wide variety of amino acids in the Xaa position, although proline would be the prototypical residue at that position. The residues in the Xaa position can be the same or can vary in identity along a single molecule.
The examples below describe the chemical synthesis of a collagen having the sequence (XaaFlpGly)n. The present invention is intended to encompass a molecule comprising the sequence, regardless of the mode of synthesis. It is anticipated that one skilled in the art of synthesizing biopolymers could make the peptide by using a modification of the chemical synthesis described below. The molecule can be made by direct synthesis, as described below. It is also contemplated that the molecule can be made by fluorination of the prolines in native collagen, either by enzymatic modifications of the immature collagen form (ProProGly)n or by substitution of the hydroxyl group in Hyp in mature collagen (ProHypGly)n with a fluorine atom.
It is not presently possible to obtain the collagen mimic having the XaaFlpGly tripeptide repeat through biosynthesis. Collagen mimics obtained by chemical modification of natural collagens are within the spirit and scope of the present invention.
The success of the present invention relies on the superior electron-withdrawing ability of fluorine, relative to the hydroxyl group of hydroxyproline. It is therefore expected that a chemical modification that enhances the electron-withdrawing ability of the hydroxyl group (as opposed to replacing the hydroxyl group with a fluorine atom) will enhance collagen stability. It is anticipated that chemical modifications to the hydroxyl group of hydroxyproline that increase its electron-withdrawing ability would result in a collagen mimic with increased stability. Proposed chemical modifications of the hydroxyl group of hydroxyproline are described below.
EXAMPLE
Synthesis of Defined Mimics of Triple-helical Collagen In brief, (ProFlpGly),o was synthesized by segment condensation on a solid phase. FmocProFipGlyOH units were assembled by standard solution-phase procedures as described in Bodanszky, The Practice of Peptide Synthesis 2nd Ed., Springer-Verlag (1994), from Flp and commercial reagents. The Flp was made as described in Panasik et al., Int. J. Pept. Protein Res., 44:262-269 (1994) and Eberhardt et al., I. Am. Chem. Soc., 118:12261-12266 (1996). For each strand of a triple helical collagen mimic, ten FmocProFlpGlyOH units were coupled on Z-chlorotrityl resin using an ABI 432A peptide synthesizer. The cleaved peptide was purified by HPLC on a Vydac C-18 reversed-phase column. (ProProGly), 0 and (ProHypGly)o were from Peptides International. All three 30-mers were judged to be >90% pure by HPLC and mass spectrometry.
In more detail, the collagen mimic was synthesized by a route based on tripeptide units of the form: FmocX-Y-GlyOH, where Fmoc is Na-9fluorenylmethoxycarbonyl. The placement of a glycine residue at the C-terminus of these units avoided problems caused by racemization (via aztactone formation) during the solid-phase coupling of activated peptide fragments. The tripeptide units were synthesized by using standard solution phase techniques (Bodanszky, 1994). The units were assembled with N a -tert-butyloxycarbonyl (Boc) rather than Fmoc protecting groups because Fmoc cannot withstand Pd/C-catalyzed hydrogenolysis that is necessary to deprotect the glycine residue.
The synthetic route used to synthesize to FmocProFlpGlyOH is shown in Figure 2.
Briefly, reaction of BocFlpOSu with GlyOBn yielded a protected dipeptide.
Removal of the Boc group in acidic dioxane followed by coupling with BocProOH gives a protected tripeptide. Removal of the benzoyl group by hydrogenolysis yields the Boc analog of 1, which was converted to 1 by removal of the Boc group and reaction with FmocOSu. All reagents used in the synthesis of the tripeptides are available commercially.
Table 2: Tripeptide units used in the synthesis of collagen mimic position 1 position 2 position 3 1 FmocPro- Flp- GlyOH A peptide that mimics single strands of collagen was synthesized by solid-phase coupling of tripeptide 1. For a triple helix to be stable at ambient temperature, each strand must contain at least 7 tripeptide repeats. A collagen mimic in which each strand contains 10 tripeptide units was synthesized. This 30-mer was synthesized on 2chlorotrityl resin, which is amenable to solid-phase synthesis with Fmoc amino acids and allows for the cleavage of the polypeptide from the resin without sidechain or aamino group deprotection, Fields and Noble, Int. Pept. Protein Res., 37:513-520 (1990).
The route used to synthetic Fmoc(ProFlpGly),o-OH is shown in Figure 3. Briefly, commercial Z-chlorotrityl resin was deprotected with piperidine (Barlos et al., Int. Pept. Protein Res., 38:555-562 (1991)) and coupled with FmocProFlpGylOH using DCC and hydroxybenzotriazole (HOBt) to give a resin-bound tripeptide. The deprotection and coupling steps were repeated with tripeptide units until 9 additional units were added. The resulting 30-mer unit was deprotected to give 2 as a free acid (Table Mer peptides 3 and 4 were from Peptides International.
Table 3: 30-Mer peptides that mimic strands of collagen. Triple helices composed of units 2, 3, or 4 were used for thermodynamic measurements of collagen stability 2 H,N(ProFIpGly),,OH 3 HN(ProProGly),oOH 4 H 2 N(ProHypGly),oOH Stability of Triple Helix The triple-helical structure of collagen has a characteristic circular dichroism (CD) spectrum, with a peak signal at 225 nm. Figure 1 shows the CD spectrum of (ProFlpGly),, together with the CD spectra of (ProProGly) o and (ProHypGly),, (inset).
Each of the three collagen mimics has a strong signal at 225 nm, which is characteristic of the collagen triple helix.
The melting temperature of the helix formed by peptides 2 -4 was determined by monitoring the CD signal at 225 nm as a function of temperature, according to the method of Long, et al., Biochemistry, 32:11688-11695, (1993).
Thermal denaturation of the three collagen-related triple helices (80 AM) was performed in 50 mM acetic acid, which is a typical condition for the assessment of collagen stability. The results of this experiment are summarized in Table 4. The (ProFlpGI y),o collagen mimic has much greater thermal stability than (ProProGly), 0 and (ProHypGly),,, which is consistent with our hypothesis that the stability of collagen triple helices is related 16o th inductive effect. Also shown in Table 4 are the free energy changes for each of the three collagen mimics. These values were obtained by the method of Becktel and Schellman, Biopolymers 26:1859-1877 (1987).
Table 4. Fluoroproline Greatly Stabilizes Triple-Helical Collagen Strand Tm°C) AA G, (kcal/mol) (ProFlpGly),, 91 11 (ProHypGly) 0 69 (ProProGly),i 41 0 Each Hyp residue: 6.5 kcal/mol 30 0.2 kcal/mol Each Flp residue: 11 kcal/mol 30 0.4 kcal/mol These results suggest that the electron-withdrawing ability of the fluorine atom of Flp increases the stability of the collagen triple helix. It is expected that modifying the hydroxyl group of hydroxyproline in collagen so as to increase the electron-withdrawing ability of the hydroxyl group would result in an increase in the stability of the collagen.
Ideally, the chemical modification should: make the hydroxyl group more electron withdrawing; be small, so as not to interfere with the packing of triple helices against each other; be uncharged, so as not to interfere with the packing of triple helices against each other. Potentially useful modifications include the addition of an acetyl group, a mesyl (methanesulfonyl) group, or a trifluoromethyl group to the hydroxyl group.
It is speculated that chemical modification of natural collagen to obtain a collagen with increased stability could be obtained as follows. Briefly, natural collagen would be dissolved in an organic solvent. The solvent of choice would likely be polar (to allow the collagen to dissolve) and aprotic (so as not to react with the reagents used jn the modification). One solvent having these characteristics is pyridine. It is envisioned that a solution of collagen could be combined with a solution of the chemical modification reagent. If one wished to add an acetyl group, the modification reagent could be acetyl chloride. If one wished to add a mesyl group, the modification reagent could be mesyl chloride. If one wished to add a trifluoromethyl group, the modificati6n reagent could be trifluoromethyl iodide. Each of these reagents could also modify other hydroxyl groups and amino groups on collagen. This may be detrimental to collagen stability. However, it is anticipated that the overall effect would be an increase in stability.
Claims (13)
1. A collagen mimic comprising a tripeptide having the formula: (Xaa-Flp-Gly)n, where Xaa is any amino acid residue, Flp is 4(R)-fluoroproline, and n is a positive integer.
2. The peptide of claim 1, wherein n is at least 7.
3. The peptide of claim 1, wherein at least one amino acid residue Xaa is a proline residue.
4. A composition of matter comprising a triple helix of collagen mimic molecules in which each of the molecules in the helix comprises tripeptides of the formula: (Xaa-Flp-Gly)n, where Xaa is any naturally occurring amino acid, Flp is 4(R)-fluoroproline, and n is a positive integer.
A composition of matter as claimed in claim 4 wherein n is at least 7.
6. A composition of matter as claimed in claim 4 wherein Xaa is proline. -13- [R:\LIBFF]496010spec.doc:gcc I 14
7. A collagen mimic comprising a tripeptide having the formula: (Xaa-Xbb-Gly)n, where Xaa is any amino acid residue, Xbb is selected from the group consisting of 4(R)-fluoroproline, mesly modified hydroxyproline, and trifluoromethyl modified hydroxyproline, and n is a positive integer.
8. The peptide of claim 7, wherein n is at least 7.
9. The peptide of claim 7, wherein at least one amino acid residue Xaa is a proline residue.
10. A collagen mimic comprising a tripeptide having the formula: (Xaa-Xbb-Gly)n, where Xaa is any amino acid residue, Xbb is selected from the group consisting of 4(R)-fluoroproline, 4(S)- fluoroproline, 4,4-difluoroproline, and n is a positive integer.
11. The peptide of claim 10, wherein n is at least 7.
12. The peptide of claim 7, wherein at least one amino acid residue Xaa is a proline residue.
13. A collagen mimic, substantially as hereinbefore described with reference to any one of the examples. Dated 15 March 2006 Wisconsin Alumni Research Foundation Patent Attorneys for the Applicant/Nominated Person SPRUSON FERGUSON [R:\PAL Specifications\496010]26070spec.doc:gcc
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2003200660A AU2003200660B2 (en) | 1997-08-25 | 2003-02-25 | Collagen Mimics |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08918223 | 1997-08-25 | ||
| AU84806/98A AU8480698A (en) | 1997-08-25 | 1998-07-09 | Collagen mimics |
| AU2003200660A AU2003200660B2 (en) | 1997-08-25 | 2003-02-25 | Collagen Mimics |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU84806/98A Division AU8480698A (en) | 1997-08-25 | 1998-07-09 | Collagen mimics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2003200660A1 AU2003200660A1 (en) | 2003-05-01 |
| AU2003200660B2 true AU2003200660B2 (en) | 2006-05-25 |
Family
ID=39338612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2003200660A Expired AU2003200660B2 (en) | 1997-08-25 | 2003-02-25 | Collagen Mimics |
Country Status (1)
| Country | Link |
|---|---|
| AU (1) | AU2003200660B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10329341B2 (en) | 2006-05-26 | 2019-06-25 | Wisconsin Alumni Research Foundation | Collagen mimics |
-
2003
- 2003-02-25 AU AU2003200660A patent/AU2003200660B2/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10329341B2 (en) | 2006-05-26 | 2019-06-25 | Wisconsin Alumni Research Foundation | Collagen mimics |
| US11390662B2 (en) | 2006-05-26 | 2022-07-19 | Wisconsin Alumni Research Foundation | Collagen mimics |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5973112A (en) | Collagen mimics | |
| US5948887A (en) | Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site | |
| Foo et al. | Genetic engineering of fibrous proteins: spider dragline silk and collagen | |
| Brodsky et al. | The collagen triple-helix structure | |
| EP1124590B1 (en) | Enzyme-mediated modification of fibrin for tissue engineering | |
| Patino et al. | Collagen: an overview | |
| Przybyla et al. | Higher-order assembly of collagen peptides into nano-and microscale materials | |
| JP5583695B2 (en) | Collagen related peptides and their use and hemostatic foam substrate | |
| EP1340767B1 (en) | Polypeptide useful as biomaterial and process for producing the same | |
| US11390662B2 (en) | Collagen mimics | |
| Barth et al. | A (4R)‐or a (4S)‐fluoroproline residue in position Xaa of the (Xaa‐Yaa‐Gly) collagen repeat severely affects triple‐helix formation | |
| US20090264626A1 (en) | Stabilization of the collagen triple helix by o-methylation of hydroxyproline residues | |
| He et al. | Self-assembling triple-helix recombinant collagen hydrogel enriched with tyrosine | |
| ES2303364T3 (en) | EXTRACELLULAR MATRIX PROTEINS WITH MODIFIED AMINO ACIDS. | |
| WO2004020470A1 (en) | Process for producing collagen treated with cysteine protease and collagen treated with cysteine protease | |
| Kar et al. | Sequence dependence of kinetics and morphology of collagen model peptide self‐assembly into higher order structures | |
| Kalita et al. | Hierarchical Assemblies of Collagen-Mimetic Peptides: From a Fundamental Understanding to Developing Biomaterials | |
| Taylor et al. | Synthesis of the repeating decapeptide unit of Mefp1 in orthogonally protected form | |
| AU2003200660B2 (en) | Collagen Mimics | |
| US20040082513A1 (en) | Enzyme-mediated modification of fibrin for tissue engineering | |
| US6100044A (en) | Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site | |
| JPH06510987A (en) | Calpain inhibitory peptide homolog of kininogen heavy chain | |
| Kim | Recombinant protein polymers in biomaterials | |
| US7122521B2 (en) | Collagen mimics | |
| US5928896A (en) | Polypeptides that include conformation-constraining groups which flank a protein--protein interaction site |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |